---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-159910"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:17:37.098780+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology amends executive’s equity vesting terms tied to pending Inmagene merger

## Summary
- Effective July 15, 2025, Ikena Oncology amended employment agreement with Dr. Jotin Marango, an executive officer.
- Amendment provides for full acceleration of time-based equity awards if termination without cause or resignation during change in control period.
- Change in control period began March 18, 2025 (initial S-4 filing for merger with Inmagene) and ends 12 months post-merger.
- Accelerated vesting effective later of termination date or change in control; forfeiture of unvested portions delayed until that date.
- Contemplated merger with Inmagene Biopharmaceutics was announced December 23, 2024.

## SEC filing metadata
- accession: 0001193125-25-159910
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312525159910/0001193125-25-159910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312525159910/d948992d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-159910
- JSON: https://secwatch.observer/filing/0001193125-25-159910.json
- Plain text: https://secwatch.observer/filing/0001193125-25-159910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.